Degree in Artificial intelligence- AI
Aartificial intelligence, Algorithms, Computer Vision (CV), Deep Learning, Design, Drug Discovery, Effective communication skills, GPUs, High performance computing- HPC, Large Language Models - LLMs, Leadership Skill, Machine learning techniques, Natural Language Processing (NLP)
We are seeking a Senior AI Research Scientist to join our world-class Artificial Intelligence (AI) team and advance generative models for protein drug design.
As a Senior Research Scientist, you will use state-of-the-art generative AI and deep learning to lead innovative research projects to support our drug discovery campaigns.
We are looking for people who can draw on significant expertise in deep learning or related disciplines such as natural language processing, protein design, and computer vision, to develop innovative models that can learn from and generate new proteins.
This position can be Remote, Hybrid or Onsite in New York, NY, or Vancouver, WA.
Responsibilities
Qualifications
Preferred (but not required):
The salary range for this position is $220,000 - $284,000/year. Competitive equity package applies. Pay offered may vary considerably depending on job-related knowledge, skills, and experience, with an emphasis in machine learning, engineering, and modeling expertise.
Absci offers highly competitive salaries and benefits, including medical, dental, vision insurance, unlimited vacation, parental leave, breakfast and lunch for onsite employees, employee assistance program, voluntary life and disability insurance, annual bonus potential, possible stock options upon Board approval, and 401(k) with a generous company match.
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs.